Therapeutic options for low bone mineral density in HIV-infected subjects

Aoife G Cotter; Patrick W G Mallon

doi:10.1007/s11904-012-0117-9

Therapeutic options for low bone mineral density in HIV-infected subjects

Curr HIV/AIDS Rep. 2012 Jun;9(2):148-59. doi: 10.1007/s11904-012-0117-9.

Authors

Aoife G Cotter¹, Patrick W G Mallon

Affiliation

¹ HIV Molecular Research Group, University College Dublin, Clinical Research Centre, Nelson St., Dublin, Ireland. Aoife.cotter@ucdconnect.ie

PMID: 22528765
DOI: 10.1007/s11904-012-0117-9

Abstract

With the advent of effective antiretroviral therapy (ART), the recognition and management of long-term complications of HIV infection and ART are increasingly important for HIV physicians. Low bone mineral density (BMD) is more common in those with HIV infection and this review will outline therapeutic options for the management of low bone mineral density relevant to HIV-infected populations.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents / therapeutic use
Bone Density / drug effects*
Bone Density Conservation Agents / pharmacology
Bone Density Conservation Agents / therapeutic use*
HIV Infections / complications*
HIV Infections / drug therapy
Humans
Osteoporosis / complications
Osteoporosis / drug therapy*

Substances

Anti-HIV Agents
Bone Density Conservation Agents